Deupirfenidone Well Tolerated and Effective in Older Patients With IPF Deupirfenidone demonstrated a favorable safety and efficacy profile across age groups in IPF, including patients aged 75 years and older.

#Deupirfenidone (LYT-100), a next-generation #AntifibroticTherapy, demonstrated a favorable safety and efficacy profile across age groups of adults with #IPF, including patients aged 75 years and older. @accpchest.bsky.social

Read here: https://bit.ly/49pnRn4

#RareDisease #MedSky #CHEST2025

Premiers résultats de la phase d'extension de l'essai #ELEVATE IPF par le Dr Argyris Tzouvelekis, @yalebooks.bsky.social concernant l'utilisation de #deupirfenidone chez les patients atteints de #FPI.